Global CRISPR Gene Editing Market Report 2024

The CRISPR gene editing market size has grown exponentially in recent years. It will grow from $1.78 billion in 2023 to $2.26 billion in 2024 at a compound annual growth rate (CAGR) of 26.9%. The growth observed in the historic period can be attributed to several key factors, including an increased demand for genome editing technologies, a rise in government funding for research and development, an increase in cancer cases leading to a focus on innovative treatments, a higher prevalence of chronic diseases necessitating advanced therapeutic approaches, growing awareness about the potential of CRISPR technology, and improvements in healthcare infrastructure supporting advanced medical interventions.

The CRISPR gene editing market size is expected to see exponential growth in the next few years. It will grow to $5.92 billion in 2028 at a compound annual growth rate (CAGR) of 27.2%. The anticipated growth in the forecast period can be attributed to several significant factors, including the increasing prevalence of genetic disorders prompting the need for advanced gene editing solutions, a growing emphasis on precision medicine tailored to individual genetic profiles, rising investments in CRISPR research and development fueling innovation, the expanding geriatric population driving demand for targeted therapies, and the growing prominence of gene therapy procedures as viable treatment options. Major trends expected in this period encompass advancements in gene editing technology leading to more precise and efficient editing techniques, an expansion in the number of research studies focusing on genetic therapies and drug development, innovations in delivery methods for gene editing tools, and the adoption of CRISPR-edited agriculture for enhanced crop traits and agricultural productivity.

The growth of the CRISPR gene editing market is expected to be driven by the increasing prevalence of genetic disorders. Genetic disorders result from abnormalities in the genome, including mutations in single genes (monogenic), multiple genes (polygenic), or chromosomal anomalies. Factors contributing to the rising prevalence of genetic disorders include genetic mutations, aging populations, and consanguineous marriages. CRISPR gene editing plays a crucial role in managing genetic disorders by enabling precise and targeted modifications to DNA. Scientists use CRISPR to identify and correct specific mutations underlying genetic disorders, restoring normal function and alleviating disease symptoms, such as in cystic fibrosis and sickle cell anemia. For example, the Centers for Disease Control and Prevention reported that about 6,000 babies born in the United States have Down syndrome each year, occurring in approximately 1 in every 700 babies. This illustrates how the increasing prevalence of genetic disorders is fueling the growth of the CRISPR gene editing market.

Key players in the CRISPR gene editing market are focused on developing innovative products, such as CRISPR gene editing tools, to provide researchers with reliable and efficient solutions for rapid and simplified analysis of gene editing experiments. These tools facilitate CRISPR genome editing experiments, allowing researchers to study edited genetic material quickly and effectively, assessing how interventions have impacted the DNA sequence's function. For instance, QIAGEN, a Germany-based provider of molecular diagnostics and research technologies, introduced the QIAprep&CRISPR Kit and CRISPR Q-Primer in June 2021. These tools enable the identification of cells edited with CRISPR technologies, offering a comprehensive solution for defining knock-outs and knock-ins resulting from gene editing. Integrating liquid-based sample preparation with downstream PCR detection and Sanger sequencing, these solutions reduce experiment time by seven days compared to traditional methods.

In January 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, entered a four-year research collaboration with Beam Therapeutics. This collaboration focuses on three programs targeting rare genetic diseases affecting the liver, muscles, and central nervous system, leveraging CRISPR gene editing technology. Beam Therapeutics is a US-based biotechnology company specializing in CRISPR gene editing.

Major companies operating in the CRISPR gene editing market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., GenScript, Integrated DNA Technologies Inc., Takara Bio Inc., OriGene Technologies Inc., Intellia Therapeutics Inc., New England Biolabs, Synthego, Arbor Biotechnologies Inc., Rockland Immunochemicals Inc., Cellectis, Editas Medicine, Caribou Biosciences Inc., System Biosciences LLC, Applied StemCell, Addgene, Mirus Bio LLC, Excision BioTherapeutics Inc., GeneCopoeia Inc., ToolGen Inc., Cellecta Inc., CRISPR Therapeutics, ERS Genomics Limited.

North America was the largest region in the CRISPR gene editing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the CRISPR gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the CRISPR gene editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Clustered regularly interspaced short palindromic repeats (CRISPR) gene editing stands as a groundbreaking biotechnological tool that enables precise modifications to the DNA of living organisms. This technology harnesses a natural defense mechanism found in bacteria, where CRISPR sequences in DNA are utilized to identify and cut specific genetic sequences. CRISPR gene editing empowers scientists to add, remove, or alter genetic material with remarkable precision, making it a potent technique for research, therapeutic interventions, and potential treatments for genetic disorders.

The primary types of CRISPR gene editing encompass CRISPR-associated nuclease (Cas nuclease), guide RNA, DNA ligase, restriction endonuclease, and other related components. CRISPR-associated nuclease, commonly known as Cas nuclease, functions as molecular scissors, cleaving targeted DNA sequences as directed by CRISPR. This aspect focuses on the development and utilization of Cas proteins for precise gene editing, offering promising applications across industries such as agriculture, medicine, and biotechnology. It offers diverse services including design tools, plasmids, CRISPR-associated protein 9 (Cas9) and guide RNA (gRNA), delivery systems, and more. Additionally, it encompasses various technologies such as CRISPR/Cas9, zinc finger nucleases, and others, serving applications such as agriculture, biomedical research, industrial processes, genome engineering, disease modeling, functional genomics, and more. These solutions cater to a range of end users including academic institutions, research centers, biotech firms, contract research organizations (CROs), pharmaceutical companies, and biopharmaceutical companies.

The CRISPR gene editing market research report is one of a series of new reports that provides CRISPR gene editing market statistics, including the CRISPR gene editing industry global market size, regional shares, competitors with CRISPR gene editing market share, detailed CRISPR gene editing market segments, market trends, and opportunities, and any further data you may need to thrive in the CRISPR gene editing industry. These CRISPR gene editing market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The CRISPR gene editing market includes of revenues earned by entities by providing services such as gRNA design and vector construction, cell line and engineering, screening services, drug development services, and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR gene editing market also includes sales of gene editing vectors, laboratory equipment, kits and enzymes, libraries, design tools, antibodies, bioinformatics tools, and cell culture equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.